Optimi Health Announces $3.45 Million Convertible Financing and Extension of Secured Term Loan
Optimi Health (OTCQX: OPTHF), a Canadian manufacturer of GMP-grade MDMA and natural psilocybin, has announced a CAD$3.45 million convertible debenture financing and the extension of a secured term loan. The convertible debentures, priced at CAD$1,000 each, will bear a 15% annual interest rate and are convertible into common shares at $0.15 per share.
The company has also extended its CAD$1 million secured term loan to April 30, 2026, which carries a 7.5% annual interest rate. As part of the loan extension, Optimi issued 400,000 warrants exercisable at $0.25 per share for two years.
The convertible financing involves two insiders: CEO Dane Stevens and Board Chair JJ Wilson, who will hold 12.29% and 8.52% of the company respectively post-transaction.
Optimi Health (OTCQX: OPTHF), un produttore canadese di MDMA di qualità GMP e psilocibina naturale, ha annunciato un finanziamento tramite cambiali convertibili da 3,45 milioni di CAD e l'estensione di un prestito a termine garantito. Le cambiali convertibili, dal valore nominale di 1.000 CAD ciascuna, prevedono un tasso di interesse annuo del 15% e sono convertibili in azioni ordinarie a 0,15 CAD per azione.
L'azienda ha inoltre esteso il suo prestito a termine garantito da 1 milione di CAD fino al 30 aprile 2026, con un tasso di interesse annuo del 7,5%. Come parte dell'estensione del prestito, Optimi ha emesso 400.000 warrant esercitabili a 0,25 CAD per azione per un periodo di due anni.
Il finanziamento convertibile coinvolge due dirigenti interni: il CEO Dane Stevens e il Presidente del Consiglio JJ Wilson, che deteranno rispettivamente il 12,29% e l'8,52% della società dopo la transazione.
Optimi Health (OTCQX: OPTHF), un fabricante canadiense de MDMA de grado GMP y psilocibina natural, ha anunciado una financiación mediante bonos convertibles por 3,45 millones de CAD y la extensión de un préstamo a plazo garantizado. Los bonos convertibles, con un precio de 1.000 CAD cada uno, devengan un interés anual del 15% y son convertibles en acciones ordinarias a 0,15 CAD por acción.
La compañía también ha extendido su préstamo a plazo garantizado de 1 millón de CAD hasta el 30 de abril de 2026, con una tasa de interés anual del 7,5%. Como parte de la extensión del préstamo, Optimi emitió 400.000 warrants ejercitables a 0,25 CAD por acción durante dos años.
La financiación convertible involucra a dos directivos internos: el CEO Dane Stevens y el presidente del consejo JJ Wilson, quienes poseerán respectivamente el 12,29% y el 8,52% de la compañía después de la transacción.
Optimi Health (OTCQX: OPTHF)는 캐나다의 GMP 등급 MDMA 및 천연 실로시빈 제조업체로, 345만 캐나다 달러 규모의 전환 사채 금융과 담보 대출 기간 연장을 발표했습니다. 전환 사채는 각 1,000 캐나다 달러로 책정되었으며, 연 15%의 이자율이 적용되고 주당 0.15 캐나다 달러에 보통주로 전환 가능합니다.
회사는 또한 100만 캐나다 달러 담보 대출을 2026년 4월 30일까지 연장했으며, 연 7.5%의 이자율이 적용됩니다. 대출 연장의 일환으로 Optimi는 40만 워런트를 발행했으며, 이는 주당 0.25 캐나다 달러에 2년간 행사할 수 있습니다.
이번 전환 금융에는 내부 임원 두 명이 참여했으며, CEO Dane Stevens와 이사회 의장 JJ Wilson은 각각 거래 후 회사 지분의 12.29%와 8.52%를 보유하게 됩니다.
Optimi Health (OTCQX: OPTHF), un fabricant canadien de MDMA de qualité GMP et de psilocybine naturelle, a annoncé un financement par débentures convertibles de 3,45 millions de CAD ainsi que la prolongation d'un prêt à terme garanti. Les débentures convertibles, au prix de 1 000 CAD chacune, portent un taux d'intérêt annuel de 15% et sont convertibles en actions ordinaires à 0,15 CAD par action.
L'entreprise a également prolongé son prêt à terme garanti de 1 million de CAD jusqu'au 30 avril 2026, avec un taux d'intérêt annuel de 7,5%. Dans le cadre de cette extension, Optimi a émis 400 000 bons de souscription exerçables à 0,25 CAD par action pendant deux ans.
Le financement convertible implique deux initiés : le PDG Dane Stevens et le président du conseil JJ Wilson, qui détiendront respectivement 12,29% et 8,52% de la société après la transaction.
Optimi Health (OTCQX: OPTHF), ein kanadischer Hersteller von GMP-zertifiziertem MDMA und natürlichem Psilocybin, hat eine wandelschuldverschreibung im Wert von 3,45 Millionen CAD sowie die Verlängerung eines gesicherten Terminkredits bekannt gegeben. Die Wandelanleihen, mit einem Nennwert von 1.000 CAD pro Stück, tragen einen jährlichen Zinssatz von 15% und sind wandelbar in Stammaktien zu 0,15 CAD pro Aktie.
Das Unternehmen hat zudem seinen gesicherten Terminkredit über 1 Million CAD bis zum 30. April 2026 verlängert, der mit einem jährlichen Zinssatz von 7,5% versehen ist. Im Rahmen der Kreditverlängerung hat Optimi 400.000 Warrants ausgegeben, die zu 0,25 CAD pro Aktie über zwei Jahre ausgeübt werden können.
Die Wandelanleihe-Finanzierung umfasst zwei Insider: CEO Dane Stevens und Vorstandsvorsitzender JJ Wilson, die nach der Transaktion jeweils 12,29% und 8,52% des Unternehmens halten werden.
- None.
- High interest rate of 15% on convertible debentures indicates expensive financing
- Potential dilution from conversion of debentures at $0.15 per share
- Related party transaction with significant insider involvement
- Additional warrant issuance creates further potential dilution
Vancouver, British Columbia--(Newsfile Corp. - July 18, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian drug manufacturer and formulator of GMP-grade MDMA and natural psilocybin, is pleased to announce that it has entered into subscription agreements pursuant to which it proposes to complete a non-brokered private placement (the "Offering") with two non-arm's length parties (each an "Investor") of 3,450 unsecured convertible debentures of the Company (each a "Convertible Debenture") at a price of CAD
The principal amount of the Convertible Debentures, in whole or in part, will be convertible into Common Shares at the Conversion Price at the option of the Investors and for no additional consideration upon written notice from the Investor to the Company at any time prior to the close of business on the Maturity Date. Upon conversion of all or any of the Convertible Debentures, all accrued and unpaid interest outstanding to the date of the conversion on any such converted Convertible Debenture shall be paid in cash or in Common Shares at the election of the Investor. In the event that the Investor elects to convert all or a part of the accrued and unpaid interest into Common Shares, such Common Shares shall be issued at a deemed price equal to the most recent closing price of the Common Shares on the CSE prior to the receipt by the Company of a conversion notice from the Investor.
The net proceeds received by the Company from the Offering will be used for general working capital. All securities issued under the Offering, including securities issuable on conversion thereof, will be subject to a hold period expiring four months and a day from the date of issuance, in accordance with the rules and policies of the CSE and applicable Canadian securities laws. The Offering is expected to close on or about July 24, 2025. The Offering constitutes a "related party transaction" as defined in Multilateral Instrument 61-101 - Protection of Minority Securityholders in Special Transactions ("MI 61-101"), as the Investors are Mr. Dane Stevens, CEO, CMO and a director of the Company, by way of Cathay Visions Enterprises Ltd. and Mr. JJ Wilson, Chair of the Board and a director of the Company, by way of Catcher Investments Ltd. Following the acquisition Mr. Stevens holds 11,875,566 Common Shares or
Extension of Secured Term Loan
The Company also announces it has entered into an extension to its non-dilutive Debt Financing Agreement ("DFA") and General Security Agreement ("GSA") for CAD
About Optimi Health Corp.
Optimi Health Corp. is a Health Canada-licensed, GMP-compliant manufacturer and supplier of natural psilocybin and MDMA. Dedicated to producing high-quality psychedelic products, the Company aims to support the global advancement of mental health therapies through rigorous compliance, innovation, and collaboration.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10615/259200_c1250a48942c3bec_001full.jpg
On Behalf of the Board
JJ Wilson, Chair of the Board
For more information, please contact:
Optimi Health Corp.
Telephone: (778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca
Forward-Looking Statements
This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements"). Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies, certain of which are unknown. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements. These statements may involve estimates, assumptions, and uncertainties that could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct, and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.
Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed in the Company's long form prospectus dated February 12, 2021, a copy of which is available on SEDAR+ at www.sedarplus.com. Except as expressly required by applicable law, Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/259200
FAQ
What is the size and terms of Optimi Health's (OPTHF) convertible financing announced on July 18, 2025?
Who are the main investors in Optimi Health's July 2025 convertible financing?
What are the terms of Optimi Health's loan extension announced in July 2025?
How will Optimi Health use the proceeds from the July 2025 convertible financing?
What is the potential dilution impact of Optimi Health's July 2025 financing?
